Alector (ALEC) Competitors $1.40 -0.08 (-5.41%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. UPB, SAGE, ALT, TNGX, KROS, RLAY, AUTL, ARVN, DNTH, and MNMDShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Autolus Therapeutics (AUTL), Arvinas (ARVN), Dianthus Therapeutics (DNTH), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Upstream Bio Sage Therapeutics Altimmune Tango Therapeutics Keros Therapeutics Relay Therapeutics Autolus Therapeutics Arvinas Dianthus Therapeutics Mind Medicine (MindMed) Alector (NASDAQ:ALEC) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Is ALEC or UPB more profitable? Upstream Bio has a net margin of 0.00% compared to Alector's net margin of -139.74%. Upstream Bio's return on equity of 0.00% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-139.74% -100.58% -25.15% Upstream Bio N/A N/A N/A Do analysts recommend ALEC or UPB? Alector presently has a consensus target price of $4.00, suggesting a potential upside of 185.71%. Upstream Bio has a consensus target price of $56.50, suggesting a potential upside of 414.57%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ALEC or UPB? In the previous week, Upstream Bio had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Alector. Upstream Bio's average media sentiment score of 0.93 beat Alector's score of 0.44 indicating that Upstream Bio is being referred to more favorably in the news media. Company Overall Sentiment Alector Neutral Upstream Bio Positive Which has better valuation and earnings, ALEC or UPB? Upstream Bio has lower revenue, but higher earnings than Alector. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M1.39-$119.05M-$1.26-1.11Upstream Bio$2.37M249.20-$62.81MN/AN/A Do institutionals & insiders hold more shares of ALEC or UPB? 85.8% of Alector shares are owned by institutional investors. 9.1% of Alector shares are owned by company insiders. Comparatively, 13.6% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryUpstream Bio beats Alector on 11 of the 13 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.99M$2.82B$5.46B$8.91BDividend YieldN/A2.71%5.36%4.15%P/E Ratio-1.1121.2926.4619.70Price / Sales1.39251.58404.54108.31Price / CashN/A41.2925.8827.49Price / Book1.097.247.925.42Net Income-$119.05M-$55.05M$3.15B$248.34M7 Day Performance1.82%1.83%2.20%2.41%1 Month Performance4.09%6.06%4.39%4.80%1 Year Performance-69.16%0.66%32.26%17.50% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.8358 of 5 stars$1.40-5.4%$4.00+185.7%-67.4%$139.99M$100.56M-1.11270UPBUpstream Bio1.8425 of 5 stars$10.88+2.3%$56.50+419.3%N/A$585.28M$2.30M0.0038High Trading VolumeSAGESage Therapeutics3.1965 of 5 stars$9.30+1.9%$8.93-3.9%-15.7%$582.37M$41.24M-1.60690ALTAltimmune2.2736 of 5 stars$7.05+4.0%$20.20+186.6%-47.4%$571.66M$20K-5.5950Analyst ForecastGap DownHigh Trading VolumeTNGXTango Therapeutics2.254 of 5 stars$5.16+7.5%$12.20+136.4%-41.6%$559.31M$40.99M-4.2390High Trading VolumeKROSKeros Therapeutics4.1032 of 5 stars$13.49-0.4%$30.56+126.5%-70.5%$547.96M$3.55M-74.94100Positive NewsRLAYRelay Therapeutics2.8982 of 5 stars$3.19-5.1%$17.67+453.8%-49.4%$546.93M$10.01M-1.43330AUTLAutolus Therapeutics2.8356 of 5 stars$2.05-0.5%$9.32+354.6%-33.6%$545.59M$10.12M-2.33330Positive NewsARVNArvinas3.4318 of 5 stars$7.44-0.4%$20.29+172.7%-71.7%$543.05M$263.40M-11.27420DNTHDianthus Therapeutics1.6238 of 5 stars$16.85-3.4%$53.00+214.5%-31.9%$541.90M$6.24M-5.8580MNMDMind Medicine (MindMed)2.4526 of 5 stars$7.05-0.6%$25.50+261.7%-9.2%$532.63MN/A-5.4740 Related Companies and Tools Related Companies Upstream Bio Alternatives Sage Therapeutics Alternatives Altimmune Alternatives Tango Therapeutics Alternatives Keros Therapeutics Alternatives Relay Therapeutics Alternatives Autolus Therapeutics Alternatives Arvinas Alternatives Dianthus Therapeutics Alternatives Mind Medicine (MindMed) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
